Effect of intravenous ferric derisomaltose on outcomes in heart failure with or without ischaemic heart disease in the IRONMAN trial.

11 May 2024 (08:00 - 20:00)
Organised by: Logo
Congress Presentation Part of: Tailoring heart failure therapies on patient profiles Pharmacotherapy HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)
You may be interested in

ESC 365 is supported by

ESC 365 is supported by